Terms: = Bone cancer AND PAM50
8 results:
1. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV; Conte P; Bisagni G; Bartolini S; Frassoldati A; Generali D; Piacentini F; Griguolo G; Tagliafico E; Brasó Maristany F; Chic N; Paré L; Miglietta F; Vicini R; D'Amico R; Balduzzi S; Prat A; Guarneri V
J Natl Cancer Inst; 2024 Jan; 116(1):69-80. PubMed ID: 37676829
[TBL] [Abstract] [Full Text] [Related]
2. Targeting the ERβ/HER Oncogenic Network in
Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
[TBL] [Abstract] [Full Text] [Related]
3. Gene expression profiles of breast cancer metastasis according to organ site.
Brasó-Maristany F; Paré L; Chic N; Martínez-Sáez O; Pascual T; Mallafré-Larrosa M; Schettini F; González-Farré B; Sanfeliu E; Martínez D; Galván P; Barnadas E; Salinas B; Tolosa P; Ciruelos E; Carcelero E; Guillén C; Adamo B; Moreno R; Vidal M; Muñoz M; Prat A
Mol Oncol; 2022 Jan; 16(1):69-87. PubMed ID: 34051058
[TBL] [Abstract] [Full Text] [Related]
4. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
Prat A; Chaudhury A; Solovieff N; Paré L; Martinez D; Chic N; Martínez-Sáez O; Brasó-Maristany F; Lteif A; Taran T; Babbar N; Su F
J Clin Oncol; 2021 May; 39(13):1458-1467. PubMed ID: 33769862
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
Lluch A; González-Angulo AM; Casadevall D; Eterovic AK; Martínez de Dueñas E; Zheng X; Guerrero-Zotano Á; Liu S; Pérez R; Chen K; Chacón JI; Mills GB; Antolín S; Blancas I; López-Serra P; Carrasco E; Caballero R; Prat A; Rojo F; Gonzalez-Perez A; Meric-Bernstam F; Albanell J
Eur J Cancer; 2019 Oct; 120():54-64. PubMed ID: 31491604
[TBL] [Abstract] [Full Text] [Related]
6. Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases.
Priedigkeit N; Watters RJ; Lucas PC; Basudan A; Bhargava R; Horne W; Kolls JK; Fang Z; Rosenzweig MQ; Brufsky AM; Weiss KR; Oesterreich S; Lee AV
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878133
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract] [Full Text] [Related]
8. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract] [Full Text] [Related]
